Metotressato Teva (Methotrexate)

Methotrexate blocks dihydrofolate reductase, lowering tetrahydrofolate levels. This limits the synthesis of nucleotides needed for DNA, RNA and protein production, which suppresses rapidly dividing immune cells and cancer cells, providing both immunosuppressive and antineoplastic effects.

The prescribed dose of Metotressato Teva is individualized by the treating physician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No standard dose is provided here; the prescriber sets the regimen.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and harm the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Both methotrexate and azathioprine suppress immune activity, but methotrexate acts by inhibiting folate metabolism, while azathioprine interferes with purine synthesis. Methotrexate is often preferred for rheumatoid arthritis and psoriasis due to its efficacy and dosing schedule, whereas azathioprine may be chosen for organ transplantation or specific autoimmune conditions.

Store Metotressato Teva at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing to maintain stability.

Metotressato Teva is supplied as a sterile injectable solution and can be given via epidural, intra‑articular or intramuscular injection. The route, site and frequency are determined by the prescribing clinician according to the therapeutic indication.

Serious risks include severe liver toxicity (hepatitis or fibrosis), pulmonary fibrosis, and bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia. Patients should be monitored regularly for liver enzymes, respiratory symptoms and complete blood counts to detect these complications early.

Methotrexate should not be used by individuals who are pregnant, planning pregnancy, or breastfeeding. It is also contraindicated in patients with severe renal or hepatic impairment, active infections, or known hypersensitivity to methotrexate or any component of the formulation.